iBio, Inc.
IBIO Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.71
KIRA · Stoqly’s AI analyst, in plain words
- iBio, Inc. had $0.1M of revenue in fiscal 2026, down 75.0% on the year before. Over five years, revenue changed −46.9% a year on average.
- Its operating margin was −35,141.0%, down 30,490.5 pts: of every 100 in sales, about −35,141 is left after running the business.
- iBio, Inc. lost $33.0M in fiscal 2026.
- Free cash flow was −$23.8M in fiscal 2026, −23,796.0% of revenue.
Market cap
$73.6M
P/E
—
Revenue
$0.1M
Net income
−$33.0M
Free cash flow
−$23.8M
Operating margin
−35,141.0%
iBio, Inc. in 30 seconds · fiscal 2026
Are sales growing?
−75.0%
No. Sales fell 75.0% last year.
Does it make a profit?
−33,044.0%
No. It lost money last year.
Does profit turn into cash?
−23,796.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What iBio, Inc. does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Aug 28, 2026
- Legal name
- iBio, Inc.
- CIK
- 0001420720
iBio, Inc. · IBIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.9M | $0.0M | $0.2M | $0.4M | $0.1M |
| Revenue growth | −20.5% | −100.0% | — | 77.8% | −75.0% |
| Gross margin | 115.0% | — | — | — | — |
| Operating margin | −1,576.3% | — | −7,392.9% | −4,650.5% | −35,141.0% |
| Net income | −$50.3M | −$65.0M | −$24.9M | −$18.4M | −$33.0M |
| Net margin | −2,670.0% | — | −11,069.8% | −4,594.3% | −33,044.0% |
| Diluted EPS | −$5.78 | −$106.19 | −$6.50 | −$1.75 | −$0.32 |
| Cash | |||||
| Cash from operations | −$37.5M | −$30.4M | −$18.6M | −$15.3M | −$23.2M |
| Capital expenditure | $7.3M | $5.7M | $0.2M | $0.0M | $0.6M |
| Free cash flow | −$44.8M | −$36.2M | −$18.8M | −$15.3M | −$23.8M |
| FCF margin | −2,378.5% | — | −8,339.6% | −3,830.0% | −23,796.0% |
| Share count change | 11.5% | −93.0% | 526.0% | 174.1% | 891.1% |
| Debt and strength | |||||
| Cash and short-term investments | $22.7M | $4.3M | $14.2M | $8.6M | $88.0M |
| Shareholders' equity | $63.5M | $15.4M | $21.3M | $14.9M | $85.7M |
| Current ratio | 1.5x | 1.2x | 4.1x | 1.6x | 7.9x |
| Interest coverage | −21.0x | −353.5x | −96.7x | −87.7x | −663.0x |
| Returns and quality | |||||
| Return on equity | −58.5% | −164.9% | −135.7% | −101.5% | −65.7% |
| Return on tangible equity | −50.5% | −293.3% | −156.1% | −228.8% | −39.4% |
| Piotroski F-score | 3 | 2 | 4 | 3 | 3 |
| Altman Z'' | −6.5 | −26.4 | −33.8 | −49.2 | −2.4 |
Insiders bought, 12 months
$0.1M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
iBio, Inc. · IBIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.71 a share, the company is worth $73.6M.
Source: SEC EDGAR XBRL filings (CIK 0001420720). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.